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The delayed effect of growth hormone on renal function in humans.
Growth hormone is reported to increase renal plasma flow (RPF) and
glomerular filtration rate (GFR) in some but not all studies. The
discrepant results could be due to a delay in the effects of growth
hormone on renal function. We therefore examined whether a growth
hormone injection does increase RPF and GFR, whether this increase is
delayed, and whether elevation in RPF and GFR is associated with
increased plasma levels of insulin-like growth factor I (IGF-l). Seven
normal adults received a single intramuscular injection of growth
hormone, 0.15 mg/kg, and serial PAH and inulin clearances were then
monitored for three consecutive days. Plasma growth hormone levels
peaked an average of 2.25 hours after injection, at 128 12 SEM ng/ml,
and then began to decrease; on the second day values were only slightly
elevated and on the third day they were not different from baseline.
Plasma IGF-I, analyzed by direct radioimmunoassay, did not change on
the first day during 5.5 hours of measurements after injection. By the
second day, plasma IGF-I was elevated to over twice baseline levels (P
< 0.05) and remained elevated on the third day (P < 0.05). RPF and
GFR did not change from baseline (546 19 and 100 3 ml/min/l.73
m2, respectively) during the 5.5 hours after injection on the first day. By
the second day, RPF had risen to 715 21, P < 0.05, and GFR to 130
5 ml/min/l.73 m2, P < 0.05, and mean values remained elevated on
the third day. The grand mean for total renal vascular resistance was
decreased on the second and third days. Thus, after a growth hormone
injection there was a rise in RPF and GFR which was delayed, was
observed after plasma growth hormone levels had fallen to baseline,
and which occurred in association with the increased plasma IGF-I
levels. These findings suggest that growth hormone increases RPF and
GFR indirectly through one or more mediators, one of which could be
IGF-I.
The evidence regarding whether growth hormone injections
increase renal plasma flow (RPF) and glomerular filtration rate
(GFR) in man has been confusing [1—3]. In two studies, daily
injections of growth hormone into normal volunteers for four or
seven days significantly increased RPF and GFR [1,2]. In
contrast, during a two hour infusion of growth hormone into
normal adults, no change in RPF or GFR was found [31. Also,
we have observed that the acute increase in RPF and GFR
stimulated by the intravenous infusion of arginine HCI in adults
with growth hormone deficiency was similar to normal adults
[4]. These observations are consistent with the possibility that
growth hormone does not directly increase RPF and GFR but
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affects renal function by stimulating the release of another
mediator; the time required for the release and action of this
mediator causes a temporal delay in the effects of growth
hormone on the kidney. One such compound known to be
released by growth hormone is insulin-like growth factor I
(IGF-I) [5—111. Recently, we observed in a growth hormone-
deficient patient given daily growth hormone injections that the
rise in RPF and GFR was more temporally associated with a
delayed rise iii plasma IGF-I levels than with the increase in
plasma growth hormone [12].
The following study was designed in order to define in more
detail: (a) whether a single GH injection in normal subjects does
induce a rise in RPF and GFR; (b) the period of time in which
this rise may occur; and (c) whether plasma IGF-I is elevated
when the RPF and GFR are increased.
Methods
Seven normal adults, three women and four men, were
admitted to the Clinical Research Center at Harbor-UCLA
Medical Center, just before 7:00 a.m., for three consecutive
days of study. Each subject was shown to have a negative
medical history for renal disease, a normal physical examina-
tion, and a normal routine chemistry panel. Four individuals
were Caucasian; one was Black, and two were Asian. Their
mean age was 25 years (range, 19 to 32 years). Body weight was
67.6 4.6 (sEM) kg. Informed consent as approved by the
Harbor-UCLA Medical Center Human Subjects Committee
was obtained from each individual.
For three consecutive nights starting the evening before the
first day of study, the subjects fasted for 12 hours, from 7:00
p.m. until 7:00 a.m., except for water which was taken ad
libitum. The individuals continued to fast, except for water,
throughout the period of clearance measurements on each of
the three days. Between 7:00 a.m. and 8:00 a.m. each day,
subjects drank 7 mI/kg of deionized water; between 8:00 and
8:30 a.m. they drank an additional 4 mI/kg of water. Thereafter,
while timed urine collections were being performed, individuals
ingested 200 ml of water every half hour.
Cannulas were inserted into one forearm vein for infusion and
into the contralateral forearm vein to withdraw blood. At 8:00
a.m. an acute injection of inulin, 50 mg/kg (American Critical
Care, McGaw Park, Illinois, USA), and para-aminohippuric
acid, 8 mg/kg (PAH, Merck, Sharp and Dohme, West Point,
Pennsylvania, USA), was given intravenously. Immediately
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thereafter, a continuous infusion of inulin and PAH in normal
saline, 0.50 and 0.25 mg/kg/mm, respectively, was started. This
infusion was given at a rate of 30 ml/hr throughout the clearance
measurements on each of the three days of study. This proce-
dure maintained plasma inulin and PAH concentrations fairly
constant at about 25 mg/dl and 2.5 mg/dl, respectively.
One hour was allowed for equilibration. Then, at 9:00 a.m.,
subjects emptied their bladder, and urine collection periods of
30 minutes each were begun. On the first day 15 consecutive,
30-minute urine clearance periods were performed. The indi-
viduals remained at bedrest during the clearance studies, except
that they stood or used a commode to urinate. On the second
and third days, these procedures were carried out in an identical
manner, except that: 1) the inulin and PAH injections and
infusions were started at 9:00 a.m.; and 2) only four, 30-minute
urine collections were carried out, between 10:00 a.m. and
12:00 noon.
At the midpoint of each collection period, a blood sample was
obtained for the measurement of plasma inulin and PAH
concentrations. Blood pressure was measured with an arm cuff
during each urine clearance period immediately before the
blood was obtained. Hematocrit was measured every two
hours. On the first day of the study, plasma growth hormone
and IGF-I concentrations were measured at 10:15 a.m., 10:45
a.m., 11:15 a.m. and every hour thereafter until the end of the
clearance studies. On the second and third days, plasma levels
of both hormones were measured at 11:00a.m. and 12:00 noon.
After the urine collections ended on each of the first two days of
the experiment, the individuals ingested approximately the
same quantities of protein, energy and sodium as they con-
sumed prior to beginning the study. All food intake was
completed by 7:00 p.m., at which time the subjects began their
overnight fast.
On the first day of study, the first four clearance periods were
considered baseline. At 11:00 a.m. on that day, at the end of
these four periods, subjects received an intramuscular injec-
tion, 0.15 mg/kg, of the human growth hormone analogue,
Somatrem (ProtropinR, Genentech Inc., South San Francisco,
California, USA). Somatrem is produced by recombinant DNA
techniques.
Plasma and urine samples were analyzed for inulin and PAH
with the indole and diazo methods, respectively [13,14]. Plasma
growth hormone was measured with a radioimmunoassay using
the specific polyclonal rabbit antihuman growth hormone anti-
body at a dilution of 1/50,000 (raised by Dr. Odell, formerly
Torrance, California, USA). The WHO-Standard No. 66/217
and anti-rabbit gamma globulin (Dr. R. Henninger, Provo,
Utah, USA) as a second antibody were used. Native human
growth hormone and somatrem (methionylsomatotropin) share
similar antigenicity, as demonstrated by other workers who
examined this question with the use of 13 different monoclonal
antibodies [15]. Sodium in plasma and urine was measured with
a flame photometer. Plasma IGF-I levels were measured by
radioimmunoassay using a non-equilibrium incubation proce-
dure with a commercially available kit (Nichols Institute, San
Juan Capistrano, California, USA). This assay employs a highly
specific anti-IGF-I antibody which is considered not to cross-
react with the binding proteins or other peptides (personal
communication, Dr. Pandian, Nichols Institute). Unextracted
plasma was used in the radioimmunoassay. This direct assay
dOes not measure plasma total IGF-I, and growth hormone
injections are reported to increase the synthesis and the plasma
concentrations of IGF-I binding proteins. An increase in these
carrier proteins could trap labeled IGF-I in the radioimmuno-
assay, thereby resulting in falsely-elevated measured nonex-
tracted IGF-I values. However, short term (that is, 1 to 3 days)
treatment of growth hormone-deficient patients with growth
hormone doses similar to that used in our study did not raise
plasma IGF-I binding proteins [16]. Moreover, the plasma
concentrations of extracted (that is, total) and unextracted
IGF-t appear to change proportionately [17,18], and both free
and bound IGF-I should increase after GH injection [lii. Thus,
after GH injection, changes in nonextracted plasma IGF-I
probably reflect changes n total IGF-I.
In this study the renal extraction of PAH (EPAH) was not
measured. A value previously reported for normal subjects
(EPAH = 0.85) was used for calculation of the renal plasma flow
(RPF) [19,20] in order to obtain a more accurate estimate of the
true renal plasma flow. We assumed that EPAH was constant
throughout the three days of study in each subject. GFR was
calculated as the inulin clearance. The following formulas were
used to calculate RPF and total renal vascular resistance
(TRVR):
RPF CPAH/EPAH
TRVR = MABP (1 — HCT)
RPF
RPF is expressed in ml/min/l.73 m2. TRVR is not corrected for
body surface area and is expressed in mm Hglmllmin. MABP
refers to the mean arterial blood pressure and is calculated as
the diastolic blood pressure plus one-third of the pulse pressure
difference. HCT refers to the hematocrit and is expressed as a
fraction of the blood volume.
For statistical evaluation, analysis of variance was per-
formed. If a statistical difference was observed, then the
Duncan's multiple comparison test was carried out to ascertain
which groups were different from each other [21]. Statistical
significance was determined as P <0.05. Data are presented as
the mean and standard error of the mean.
Results
The results are shown in Figure 1 and Table 1. Within 30
minutes of the growth hormone injection, plasma growth hor-
mone levels had risen significantly above baseline levels. The
average concentration of plasma growth hormone reached its
highest value, 128 12 ng/ml, at 2.25 hours after the injection;
the time until attainment of the peak levels in individual
subjects ranged from 1.25 to 4.25 hours after injection. There-
after, the values declined slowly (Fig, I). By the second day,
the two plasma growth hormone values obtained from every
subject were not different from baseline (2.8 0.81, P:NS, and
2.1 0.4 ng/ml, P:NS, respectively). On the third day, plasma
growth hormone levels were at or below baseline in all subjects
(Fig. 1, Table 1).
At baseline, nonextracted plasma IGF-I levels averaged 0.74
0.08 U/mI. On the first day, there was no change in the
plasma IGF-I concentrations during the entire 5.5 hours of
study following the growth hormone injection (Fig. 1, Table 1).
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Fig. 1. Nonextracted plasma insulin-like
growth factor-I (IGF-I) and growth hormone
(GH), mean arterial blood pressure (MABP),
total renal vascular resistance (RVR),
filtration fraction (FF), renal plasma flow
(RPF) and glomerular filtration rate (GFR) in
seven normal adults before (Baseline) and
after a single intramuscular injection of
growth hormone. Values are given as mean
SEM. The arrow and vertical line indicate the
time of the growth hormone injection. Note
the breaks in the chronological scale. No
measurements were made between 5.5 and 23
hours and between 24.5 and 47 hours after the
growth hormone injection. Hence, the lines
during these periods of time do not indicate
the time courses of the changes in the
parameters. Probability of significant
difference compared to baseline values; * <
0.05.
However, on the second day, 24 hours after the growth hor-
mone injection, estimated plasma IGF-I had risen in each
subject to a mean value of 1.85 0.35 U/ml (P <0.05). On day
three, the mean nonextracted plasma IGF-I concentrations had
declined slightly but not significantly to 1.47 0.26 U/mI, and
were still greater than baseline levels (P < 0.05).
Despite marked increases in plasma growth hormone concen-
trations, there was no change in RPF on the first day during the
5.5 hours after the injection (Fig. 1, Table I). However, 23
hours later, RPF had risen above baseline in all subjects, by an
average of +32 5% (P < 0.05). On the third day, the grand
mean of the RPF values was still +22 6% above baseline (P
<0.05; Fig. 1, Table I). The RPF on day 3 was not significantly
lower than on day 2.
As with RPF, there was no change in GFR during the first day
of study. However, on the second day, GFR had increased
above baseline by +29 6% (P < 0.05). On the third day, the
grand mean of the GFR was still elevated above baseline, by
—
I
0
Growth hormone
iniection
2.0-1 I
160
120
80
40
0
E
. —
E
E
0.19
Li.U. 0.17
0.15
aE
Baseline
—2 —1 0 1 2 3 4 II II I It II5 6 23 24 25 47 48 49
Day 1
— j-. Day 2 -. I— Day 3
—j
Time, hours
868 Hirschberg et a!: Growth hormone and rena/function
Table 1. Renal hemodynamics, mean arteria1 blood pressure, fractional excretjon of sodium, a
growth hormone injection
n4 plasma hormone leveIs at baseline and after
Day ia Day 1b Day 2 Day 3
Baseline
Hours after growth hormone injection —2 to 0 0 to 5.5 23 to 25 47 to 49
RPFC m!/min/I.73 m2 546 19 567 46 715 2l 662 25C
GFR mi/min/I.73 m2 100 3 106 5 130 5 113 5
TRVR mm Hg minim! 0.093 0.007 0.086 0.004 0.068 0.005e 0.076 0.004
Filtration fraction 0.18 0.01 0.18 0.01 0.18 0.01 0.17 0.01
MABPmmHg 84±2 81±3 82±3 83±4
FENa % 0.96 0.24 0.95 0.12 0.75 0.06 1.34 0.09
Plasma GH ngim/ 1.34 0.36 128 l2 2.45 0.58 0.57 0.04
Plasma 1GF-I' U/mi 0.74 0.08 0.79 0.14 1.85 0.35e 1.47 0.26e
Grand mean SEM.
b Indicates the greatest (RPF, GFR, GH, IGF I) or lowest (TRVR) value observed on the first day during the 5.5 hours after the growth hormone
injection. For the time course of all of the values obtained during this period, see Figure I.
C The definitions of the abbreviations are given in the legend to Figure 1.d Since plasma was not extracted for the IGF-1 radioiinmunoassay, these values should be viewed as an estimate of total plasma IGF-I.
Significantly different from baseline, P < 0.05
+ 13 4% (P < 0.05), but it had declined significantly from the
values of the second day (P < 0.05; Fig. 1, Table 1).
TRVR also did not change after the growth hormone injection
on the first day. TRVR was significantly below baseline both on
the second day (by —25 4%, P < 0.05) and the third day (by
—17 5%, P < 0.05, Fig. 1, Table 1). When individual data
points for RPF, GFR and TRVR were analyzed separately, only
some of the values on the third day were significantly different
from baseline (Fig. 1).
MABP and filtration fraction did not change significantly
throughout the entire three day study (Fig. 1, Table 1). The
fractional excretion of sodium (FENa) was not different from
baseline values during the 5.5 hours of measurements after the
growth hormone injection on the first day. On the second day,
the values tended to be lower than on the first day, but this
difference was not statistically significant. On the third day, 48
hours after the growth hormone injection, FENa had increased
significantly above baseline values, to 1.34 0.09% (P < 0.05;
Table 1).
There was no change in the patients' body weight, measured
before commencing the water loading on each of the three days
of study. On the first day, the body weight was 67.6 4.6 kg;
on the second and third days, it was 67.6 4.6 and 67.8 5.1
kg, respectively. Hematocrit did not change significantly during
the study. Values were 42 1 vol % on the first day and 41
1 vol % and 40 1 vol % on the second and third days,
respectively. Serum sodium concentrations also did not change
during the course of the study.
Discussion
The results of this study confirm previous findings that a rise in
plasma growth hormone does not induce an acute increase in
RPF or GFR in man [3,4,121. Since plasma growth hormone
rose to unphysiologically high concentrations, it is unlikely that
the failure of RPF and GFR to increase on the first day was due
to an inadequate dose or plasma level. This dose of growth
hormone was used in order to enhance our ability to observe
any effects of growth hormone on RPF and GFR. Indeed,
significant changes in RPF, GFR and TRVR were observed by
23 hours after the growth hormone injection and were also
observed 48 hours after the injection (Fig. 1). Thus, growth
hormone does cause a delayed and sustained rise in renal
function (Fig. 1, Table 1) that occurs between 5.5 and 23 hours
of the injection. Since plasma growth hormone levels had fallen
to baseline levels by the second and third day it is unlikely that
Gil mediates the rise in RPF and GFR directly. Instead, the
data suggest that the effects of growth hormone are mediated by
one or more factors that are stimulated by a rise in growth
hormone levels.
It is possible that such agents as eicosanoids, angiotensin II,
or IGF-H may play a role in the Gil induced changes in renal
function, However, our results are consistent with the possibil-
ity that IGF-I mediates these effects of GH. The evidence for
such a role of IGF-I is as follows: 1) RPF, GFR and TRVR
remained at baseline during the initial hours after injection
when plasma growth hormone was high and nonextracted
plasma IGF-I was low. 2) The rise in RPF and GFR and the fall
in TRVR occurred approximately coincident with the increase
in plasma IGF-I and at a time when plasma growth hormone had
fallen virtually to baseline values (that is, between 5.5 hours and
23 hours after the injection). 3) On the third day of study, RPF,
GFR and IGF-I continued to be elevated, whereas plasma
growth hormone had fallen to or below baseline. It is relevant
that IGF-I receptors have been identified in cultured mouse
mesangial cells [221.
The finding that RPF, GFR, TRVR and plasma IGF-I ap-
peared to change at approximately the same time does not
prove that IGF-I caused these changes in renal function.
Indeed, the changes in renal function and plasma IGF-I both
could be caused by another factor. Moreover, in this study we
could only ascertain that these changes occurred between 5.5
and 23 hours after the GH injection. It is not known whether
these parameters changed concurrently within this 17.5 hour
window of time.
We previously studied a 30-year-old growth retarded man
who had primary growth hormone deficiency. He had never
received growth hormone therapy [12]. This individual, who
had no evidence for renal disease, had abnormally low RPF and
GFR, even when these values were normalized for his small
body surface area. The patient was given daily injections of
growth hormone. As in the present study, RPF and GFR had
risen to normal levels within 24 hours after the first injection,
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before the second dose was given, and the increase in renal
function occurred in association with the rise in nonextracted
plasma IGF-I concentrations. The present study extends these
observations by showing that healthy adults with normal
plasma growth hormone and IGF-I concentrations and normal
RPF and GFR respond similarly to a single growth hormone
injection.
Although our measurements of nonextracted plasma IGF-I
only provide an estimate of total IGF-I levels, other studies also
indicate that plasma total IGF-I increase after a GH injection
[9,111. Moreover, this increase begins after approximately eight
hours and remains elevated for about 48 hours [11,23]. These
observations are consistent with our findings that nonextracted
plasma IGF-I rises between 5.5and 23 hours after GH injection.
IGF-I (or sulphation factor, which includes IGF-I) appears to
be synthesized in proximal tubule cells [24] and in many other
tissues [10,24—30]. Hence, it is not known whether, under
normal circumstances, blood borne IGF-t affects the kidney or
whether IGF-I only acts on tissues where it is synthesized. A
mainly autocrine-paracrine action of IGF-I is suggested by
Underwood and associates [30] and D'Ercole and coworkers
[28,29]. These investigators measured the organ concentrations
of IGF-I in rats at different time intervals after injection of
growth hormone [26]. IGF-I concentrations rose sooner and at
a faster rate in the liver and kidneys than in plasma. This
suggests that plasma IGF-I may be derived, at least in part,
from IGF-I synthesized by these organs, and it raises the
question as to whether, under normal conditions, blood-borne
IGF-I may affect renal function or whether it merely reflects the
rate of IGF-I synthesis in these organs.
The data from the present study do not provide insight
concerning this question. However, these data are consistent
with the hypothesis that growth hormone increases RPF and
GFR indirectly through other mediators, and raises the possi-
bility that one of these mediators is IGF-I. Further studies are
clearly needed to define the role, if any, of IGF-I in the
regulation of renal function.
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